Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis
Clinical Pharmacology & Therapeutics · 2026-01 · 119 (1) · 46-62
DOI: 10.1002/cpt.70054 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 07.09.2025. Verfasst von Abdelrahman G Tawfik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, AHRQ HHS.
Abstract (Originalsprache)
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety. This systematic review and meta‐analysis aimed to quantify the risk of GI bleeding associated with individual NSAIDs. We searched PubMed from inception through January 2025 using MeSH and free‐text terms for “gastrointestinal bleeding” and nine commonly used NSAIDs. A random effects meta‐analysis was conducted to estimate the pooled odds ratios (ORs) for GI bleeding, with hazard ratios (HRs) and relative risks (RRs) treated as approximations of ORs due to the rare event nature of GI bleeding. Of 6,711 records screened, 25 studies met the inclusion criteria. Substantial heterogeneity in study design, populations, and outcome ascertainment was observed. Celecoxib was associated with the lowest risk of GI bleeding (OR 1.16, 95% CI: 0.84–1.61). Among non‐selective NSAIDs, ibuprofen had the lowest significant risk (OR 2.28, 95% CI: 1.71–3.03), while ketorolac showed the highest risk (OR 20.67, 95% CI: 14.56–29.34). Other agents, such as piroxicam and meloxicam, also demonstrated significantly elevated risks. The risk of GI bleeding varies widely among individual NSAIDs. Celecoxib appears to have the lowest GI risk, though cardiovascular safety must also be considered. These findings highlight the need for personalized NSAID selection and suggest that NSAIDs should not be treated as a uniform class when assessing bleeding risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
- Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
- School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
ORCID-Profile: Abdelrahman G Tawfik, Ainhoa Gomez-Lumbreras, Guilherme Del Fiol, Kensaku Kawamoto, Katy E Trinkley, Thomas Reese, Daniel C Malone
Förderung
- NHLBI NIH HHS
- AHRQ HHS
Zitieren
APA
Tawfik, A. G., Gomez-Lumbreras, A., Del Fiol, G., Kawamoto, K., Trinkley, K. E., Reese, T., Jones, A., & Malone, D. C. (2026). Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics, 119(1), 46-62. https://doi.org/10.1002/cpt.70054
Vancouver
Tawfik AG, Gomez-Lumbreras A, Del Fiol G, Kawamoto K, Trinkley KE, Reese T, et al. Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics. 2026;119(1):46-62. doi:10.1002/cpt.70054
BibTeX
@article{Tawfik2026,
author = {Tawfik, Abdelrahman G and Gomez-Lumbreras, Ainhoa and Del Fiol, Guilherme and Kawamoto, Kensaku and Trinkley, Katy E and Reese, Thomas and Jones, Aubrey and Malone, Daniel C},
title = {Nonsteroidal Anti‐Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta‐Analysis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {1},
pages = {46--62},
doi = {10.1002/cpt.70054}
}
EUVIMED